CNTA — Centessa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.19bn
- $6.03bn
- $15.00m
Centessa rises on FDA's 'orphan drug' tag for hemophilia drug
Brief: Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic And Safety Data For LB101 (PD-L1xcd47) Demonstrating Potential For Enhanced Therapeutic Index
Brief: Centessa Pharmaceuticals reports Q2 results
Brief: Centessa Pharmaceuticals Announces Addition Of Harris L. Rotman As Senior Vice President Of Regulatory Affairs
Brief: Centessa Pharmaceuticals PLC Files For Mixed Shelf Of Up To $350 Million
Centessa eyes record low after ending kidney disease drug development
Brief: Centessa Pharmaceuticals To Discontinue Clinical Development Of Lixivaptan For ADPKD
Brief: Centessa Expects To Incur Costs Of About $6 Mln To $8 Mln Relating To Lixivaptan Program Wind-Down Activities, Reduction In Headcount
Brief: Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results, Provides Business Updates
Brief: Centessa Pharmaceuticals Reports Fourth Quarter Net Loss Of $0.68 Per Share
Brief: Centessa Pharmaceuticals PLC Appoints Javad Shahidi As CEO
Brief: Centessa Pharmaceuticals Doses First Subject In Global Phase 3 Action Study Of Lixivaptan
Brief: Centessa Pharmaceuticals Initiates Global Phase 3 Action Study Of Lixivaptan In Autosomal Dominant Polycystic Kidney Disease
Brief: Centessa Pharmaceuticals Announces Addition To Nasdaq Biotechnology Index
Brief: Centessa Pharmaceuticals Announces Addition To Nasdaq Biotechnology Index
Brief: Centessa Pharmaceuticals Q3 Loss Per Share $0.45
Brief: Centessa Pharmaceuticals Demonstrates Proof-Of-Mechanism From First Three PiMZ Subjects Dosed In Part B Of Phase 1 Study
Brief: Centessa Pharmaceuticals Unit Orexia Therapeutics, And Schrödinger Announce Collaboration
Brief: Centessa Pharmaceuticals Announces $300 Mln Financing Agreement With Oberland Capital